Glucose transporter type 1 deficiency syndrome (Glut1DS): methylxanthines potentiate GLUT1 haploinsufficiency in vitro
- PMID: 11477212
- DOI: 10.1203/00006450-200108000-00015
Glucose transporter type 1 deficiency syndrome (Glut1DS): methylxanthines potentiate GLUT1 haploinsufficiency in vitro
Abstract
Methylxanthines such as caffeine and theophylline are known to inhibit glucose transport. We have studied such inhibition in the glucose transporter type 1 deficiency syndrome (Glut1DS) by erythrocyte glucose transport assays. Data from four patients with individual mutations in the GLUT1 gene are discussed: patient 1 (hemizygosity), 3 (S66F), 15 (368Ins23), and 17 (R333W). Zero-trans influx of (14)C-labeled 3-O-methyl glucose (3-OMG) into erythrocytes of patients is reduced (patient 1, 51%; 3, 45%; 15, 31%; 17, 52%) compared with maternal controls. Inhibition studies on patients 1, 3, 17, and maternal controls show an IC(50) for caffeine of approximately 1.5 mM both in controls (n = 3) and patients (n = 3) at 5 mM 3-OMG concentration. In the same two groups, kinetic studies show that 3 mM caffeine significantly decreases V(max) (p < 0.005), whereas the decrease in K(m) is significant (p < 0.01) only in the three controls and one patient (patient 3). Kinetic data from individual patients permit us to speculate that the interactions between caffeine and Glut1 are influenced by the mutation. Three mM caffeine also inhibits the transport of dehydroascorbic acid (DHA), another substrate for Glut1. The combined effects of caffeine (3 mM) and phenobarbital (10 mM) on glucose transport, as determined in patient 15 and the maternal control, show no additive or synergistic inhibition. These data indicate that caffeine and phenobarbital have similar Glut1 inhibitory properties in these two subjects. Our study suggests that Glut1DS patients may have a reduced safety margin for methylxanthines. Consumption of methylxanthine-containing products may aggravate the neurologic symptoms associated with the Glut1DS.
Similar articles
-
Effects of anticonvulsants on GLUT1-mediated glucose transport in GLUT1 deficiency syndrome in vitro.Eur J Pediatr. 2003 Feb;162(2):84-9. doi: 10.1007/s00431-002-1112-8. Epub 2002 Dec 6. Eur J Pediatr. 2003. PMID: 12548383
-
The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport.Life Sci. 2005 Mar 4;76(16):1859-72. doi: 10.1016/j.lfs.2004.10.032. Life Sci. 2005. PMID: 15698863
-
T295M-associated Glut1 deficiency syndrome with normal erythrocyte 3-OMG uptake.Brain Dev. 2011 Apr;33(4):316-20. doi: 10.1016/j.braindev.2010.06.012. Epub 2010 Jul 13. Brain Dev. 2011. PMID: 20630673
-
Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review.Eur J Pediatr. 2002 Jun;161(6):295-304. doi: 10.1007/s00431-002-0939-3. Epub 2002 Apr 16. Eur J Pediatr. 2002. PMID: 12029447 Review.
-
Glucose transporter 1 deficiency syndrome and other glycolytic defects.J Child Neurol. 2002 Dec;17 Suppl 3:3S15-23; discussion 3S24-5. J Child Neurol. 2002. PMID: 12597052 Review.
Cited by
-
Crystal structure of a bacterial homologue of glucose transporters GLUT1-4.Nature. 2012 Oct 18;490(7420):361-6. doi: 10.1038/nature11524. Nature. 2012. PMID: 23075985
-
Clinical review of genetic epileptic encephalopathies.Eur J Med Genet. 2012 May;55(5):281-98. doi: 10.1016/j.ejmg.2011.12.010. Epub 2012 Jan 25. Eur J Med Genet. 2012. PMID: 22342633 Free PMC article. Review.
-
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia.Am J Hum Genet. 2008 Dec;83(6):744-51. doi: 10.1016/j.ajhg.2008.11.001. Epub 2008 Nov 20. Am J Hum Genet. 2008. PMID: 19026395 Free PMC article.
-
Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group.Epilepsia Open. 2020 Aug 13;5(3):354-365. doi: 10.1002/epi4.12414. eCollection 2020 Sep. Epilepsia Open. 2020. PMID: 32913944 Free PMC article.
-
Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.JAMA Neurol. 2014 Oct;71(10):1255-65. doi: 10.1001/jamaneurol.2014.1584. JAMA Neurol. 2014. PMID: 25110966 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous